Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
Open Access
Abstract
Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74 years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8 mg/kg every 4 weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales (p<0.05). Proximal muscle pain disappeared within 8 weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12 weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4 weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment.Keywords
This publication has 19 references indexed in Scilit:
- 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeAnnals of the Rheumatic Diseases, 2015
- Effective Control of Polymyalgia Rheumatica With TocilizumabJCR: Journal of Clinical Rheumatology, 2013
- Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumaticaArthritis Care & Research, 2012
- 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeAnnals of the Rheumatic Diseases, 2012
- Effect of etanercept in polymyalgia rheumatica: a randomized controlled trialArthritis Research & Therapy, 2010
- Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica: Figure 1.The Journal of Rheumatology, 2010
- Prednisone plus Methotrexate for Polymyalgia RheumaticaAnnals of Internal Medicine, 2004
- Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government‐supported nationwide surveyArthritis Care & Research, 2003
- Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.2002
- An evaluation of criteria for polymyalgia rheumatica.Annals of the Rheumatic Diseases, 1979